What stage does Rock Springs Capital invest at?

Rock Springs Capital invests at the Late Stage stage.

What sectors does Rock Springs Capital focus on?

Rock Springs Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Rock Springs Capital located?

Rock Springs Capital is headquartered in Baltimore, US.

Rock Springs Capital

Venture capital

Baltimore · Late Stage · 12 people tracked

Also known as ROCK SPRINGS CAPITAL MANAGEMENT LP

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Rock Springs Capital pursues research-driven investing across healthcare sectors, combining deep scientific and clinical insight with a rigorous, fundamental approach. Founded by physician-scientists, the firm brings together sector specialists whose senior team has collaborated for over two decades. Its methodology leverages the full resources of the firm to identify healthcare innovations believed to be positioned for long-term value, emphasizing companies that address critical unmet medical needs. The firm stresses experience, continuity, shared investment discipline, and a reputation for integrity.

Invests inBiotech Digital Health Healthtech Medical Devices Baltimore United States

Source: firm website, verified Aug 25, 2026.

Stage

Late Stage

Baltimore, US

Instruments

Equity

Founded

2013

Last 12 months

2 investments

AUM

$2.4B

Tracked investments

Team · 12 people

from the firm's website

Kris Jenner· Co-Founder· Annapolis, Maryland, United Statesin

Physician (MD, D.Phil.) who co-founded Rock Springs Capital, bringing deep scientific and clinical expertise to the firm's healthcare investing.

Mark Bussard· Co-Founder· Reisterstown, Maryland, United Statesin

Physician (MD) who co-founded Rock Springs Capital, contributing clinical and scientific insight to the firm's investment approach.

Scott Schafer· Partner· Fallston, Maryland, United Statesin

Joined Rock Springs at inception after ten years as a research associate at T. Rowe Price covering medical device, biotech and healthcare companies. Holds a B.S. from Salisbury University, an M.B.A. from Loyola University, and the CFA designation.

Aidan O'Connor· General Counsel & Chief Compliance Officer

Leads legal and compliance; previously Chief Regulatory Counsel and CCO (U.S.) at SoftBank Investment Advisers, Senior Counsel at the SEC, and an attorney at Skadden. Holds a J.D. from Georgetown.

Allison Wald· Analyst

Joined Rock Springs in 2025 after completing a Ph.D. in Biomedical Engineering at Johns Hopkins, where she interned at Johns Hopkins Technology Ventures. Also earned an M.S. from Johns Hopkins and a B.S. from the University of Virginia.

Dan Lundgren· Analyst

Joined Rock Springs in 2021; previously worked in business development at Cabaletta Bio through its Series A, B and IPO, and did graduate research at the NIH. Earned a B.S. in Economics from Wharton and a B.A. in Biology from UPenn.

Matt Rosenberg· Analyst

Joined Rock Springs in 2024 after founding and selling a cloud-based practice management solution and advising healthcare clients at McKinsey. Holds an A.B. from Harvard and an M.D. from Yale.

Michael Patti· Director of Investor Relations· Baltimore, Maryland, United Statesin

Leads investor relations; previously Director of Business Development at Select Equity Group and held sales roles at Schroders, BNY Mellon, and Fidelity. Holds a B.S. from Boston University.

Nnamdi Etoh· Chief Financial Officer· Baltimore, Maryland, United Statesin

Joined Rock Springs in 2016 after serving as VP of Finance at Grand Brands and a corporate tax accountant at T. Rowe Price. Holds a B.A. from Duke and the CPA and CMA designations.

Taylor Beccone· Controller· Baltimore, Maryland, United Statesin

Joined Rock Springs in 2019 after roles as an assistant controller at Greenspring Associates and an audit associate at CohnReznick. Holds a B.S. in Accounting from Mount St. Mary's University and the CPA designation.

Temi Akande· Analyst

Joined Rock Springs in 2024 after working as an investment analyst at Alyeska Investment Group covering MedTech and healthcare services. Holds a B.S. from Oklahoma State, an M.B.A. from Wharton, and an M.P.A. from Harvard Kennedy School; formerly an aerospace engineer at American Airlines.

Veric Tan· Analyst· Baltimore, Maryland, United Statesin

Joined Rock Springs in 2024; earned B.S. degrees in Materials Science and Cognitive Science from Johns Hopkins and previously served as a lieutenant in the Singapore Armed Forces.

What they invest in

from 9 of 9 portfolio companies

Biotech ×9Healthtech ×5Medical Devices ×2AI & Machine Learning ×1

HQs:United States×5United Kingdom×2

Investments · 9 tracked

founders shown can be your intro path

By year:2026 · 1 2025 · 1 2024 · 1 2023 · 25 dated

Avalyn Pharma Incavalynpharma.com inNASDAQ: AVLNSep 2023 · $175M

Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.

BiotechHealthtech

Lyn Baranowski(CEO)in

Co-investorsAndera Partners Catalio Capital Management, LP F-Prime Capital InVivium Capital Norwest Venture Partners RiverVest Venture Partners +7 more

Xilio Therapeuticsxiliotx.com inNASDAQ: XLO

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

Rene Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)

Co-investorsBain Capital Life Sciences Bay City Capital F-Prime Capital M Ventures MRL Ventures Fund RA Capital +4 more

Apollo Therapeuticsapollotherapeutics.com in✓ verified

Apollo Therapeutics is a portfolio biopharmaceutical company that translates academic biology and medical research into new medicines, operating over 20 therapeutic programs including six in clinical development.

BiotechHealthtechCambridge, GB

Co-investorsPatient Square Capital AlbionVC UCL Technology Fund

Apollo Therapeuticsapollotx.com inSep 2023 · $226.5M✓ verified

Apollo Therapeutics is a biopharmaceutical company that translates academic biology and medical research into new medicines, operating a portfolio of over 20 therapeutic programs with several in clinical development.

BiotechCambridge, GB

Co-investorsPatient Square Capital AlbionVC

Abcuroabcuro.comAug 2026

Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.

BiotechHealthtechNewton, US

Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)

Co-investorsBain Capital Life Sciences New Enterprise Associates (NEA)RA Capital Samsara BioCapital Sanofi Ventures Mass General Brigham Ventures +8 more

City Therapeuticscitytx.com in 𝕏Oct 2024

City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands.

BiotechMedical DevicesCambridge, US

Mark Keating, MD(Co-founder)Kotaro Nakanishi, PhD(Co-founder)Yukihide Tomari, PhD(Co-founder)Phillip Zamore, PhD(Co-founder)

Co-investorsAN Venture Partners ARCH Venture Partners Sofinnova Ventures Casdin Capital Fidelity Investments Invus

Homology Medicineshomologymedicines.com

Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.

BiotechBedford, US

Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)

BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)

Co-investors5AM Ventures ARCH Venture Partners OUP (Osage University Partners)Alexandria Deerfield Management Company HBM Healthcare Investments +4 more

Synthekinesynthekine.com in 𝕏

Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.

BiotechHealthtech

K. Christopher Garcia(Founder)Susan Molineaux(CEO)Martin Oft(Chief Scientific Officer)Naiyer Rizvi(Chief Medical Officer)Gregory(Chief Technical Officer)Geoff(Chief Business Officer)

Co-investorsSamsara BioCapital The Column Group Bain Capital Life Sciences Canaan Partners RA Capital TCG Crossover +2 more

Treeline Biosciencestreeline.bioSep 2025

Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.

AI & Machine LearningBiotechMedical DevicesWatertown, US

Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)in

BoardKristina Burow(Director)inAli Satvat(Director)David Schenkein(Director)in

Co-investorsAisling Capital ARCH Venture Partners OrbiMed Casdin Capital Fidelity Investments GV (Google Ventures)+1 more

Exits · 2

IPOs and acquisitions across the tracked portfolio

Avalyn Pharma IncNASDAQ: AVLNXilio TherapeuticsNASDAQ: XLO

Portfolio news

latest coverage across their companies

Abcuro secures $66m to support clinical trial of ulviprubart for IBM

Abcuro · clinicaltrialsarena.com · Aug 19, 2026

Xilio Therapeutics (NASDAQ:XLO) Announces Quarterly Earnings Results - Ticker Report

Xilio Therapeutics · tickerreport.com · Aug 15, 2026

Neumora's Phase 3 Trial Miss and a Trio of VC Raises — Watertown Bio

Treeline Biosciences · watertown.bio · Jun 23, 2026

City Therapeutics Raises $99.5M in Series B Funding

City Therapeutics · finsmes.com · Jun 9, 2026

Avalyn Pharma closes $345 million IPO on Nasdaq By Investing.com

Avalyn Pharma Inc · investing.com · May 1, 2026

Frequently asked questions

What stage does Rock Springs Capital invest at?: Rock Springs Capital invests at the Late Stage stage.
What sectors does Rock Springs Capital focus on?: Rock Springs Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Rock Springs Capital located?: Rock Springs Capital is headquartered in Baltimore, US.

Images

Similar investors

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

DCVC (Data Collective)

DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.

$5M – $25M

Eight Roads Ventures

Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.

$5M – $30M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M

Khosla Ventures

Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.

$5K – $50M